A STUDY OF ANTI-HYPERLIPIDEMIC ACTIVITY OF MARKETED FORMULATIONS OF TERMINALIA ARJUNA POWDER USING EXPERIMENTAL ANIMAL MODEL

Abstract

Hyperlipidemia is a disorder of lipid metabolism which is major risk of coronary heart disease. Now a day’s synthetic drugs have been associated with number of side effects but herbal medicines have lipid lowering and antioxidant activities without any side effects. Some traditionally herbs like: - Commiphora mukul (Gugglul), Terminalia Arjuna (Arjun), Picrorrhiza Kurroa(Kutki), Allium Sativum (Lasuna), etc. are used as Antihyperlipidemic drug in ayurvedic literature. Hence the present study was undertaken to investigate the antihyperlipidemic effect of marketed formulations of terminalia arjuna against Triton WR-1339 induced hyperlipidemia in rats at 200 and 400 mg/kg dose inhibited the elevation of serum cholesterol and triglyceride levels in hyperlipidemic rats. Marketed formulations also significantly decreased 3-hydroxy-3-methylglutaryl- CoA reductase (HMG-CoA reductase) activity at the dose of 200mg/kg and 400mg/kg; p.o. showed good antihyperlipidemic activity in Triton WR-1339 induced hyperlipidemic rats. The probable mechanism of action of the marketed formulations may be inhibition of HMG-CoA reductase enzyme pathway.
Key Words: Antihyperlipidemic activity, marketed formulations, Triton WR 1339, HMG-CoA reductase, Sprague–Dawley rats.